In VivoSelection of Human Hematopoietic Cells in a Xenograft Model Using Combined Pharmacologic and Genetic Manipulations
- 10 December 2003
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 14 (18) , 1703-1714
- https://doi.org/10.1089/104303403322611728
Abstract
Strategies that increase the ability of human hematopoietic stem and progenitor cells to repair alkylator-induced DNA damage may prevent the severe hematopoietic toxicity in patients with cancer undergoing high-dose alkylator therapy. In the context of genetic diseases, this approach may allow for selection of small numbers of cells that would not otherwise have a favorable growth advantage. No studies have tested this approach in vivo using human hematopoietic stem and progenitor cells. Human CD34(+) cells were transduced with a bicistronic oncoretrovirus vector that coexpresses a mutant form of O(6)-methylguanine DNA methyltransferase (MGMT(P140K)) and the enhanced green fluorescent protein (EGFP) and transplanted into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Mice were either not treated or treated with O(6)-benzylguanine (6BG) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). At 8-weeks postinjection, a 2- to 8-fold increase in the percentage of human CD45(+)EGFP(+) cells in 6BG/BCNU-treated versus nontreated mice was observed in the bone marrow and was associated with increased MGMT(P140K)-repair activity. Functionally, 6BG/BCNU-treated mice demonstrated multilineage differentiation in vivo, although some skewing in the maturation of myeloid and B cells was observed in mice transplanted with granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood compared to umbilical cord blood. Expansion of human cells in 6BG/BCNU-treated mice was observed in the majority of mice previously transplanted with transduced umbilical cord blood cells. In addition, a significant increase in the number of EGFP(+) progenitor colonies in treated versus nontreated mice were observed in highly engrafted mice indicating that selection and maintenance of human progenitor cells can be accomplished by expression of MGMT(P140K) and treatment with 6BG/BCNU.Keywords
This publication has 64 references indexed in Scilit:
- Comparison of Three Retroviral Vector Systems for Transduction of Nonobese Diabetic/Severe Combined Immunodeficiency Mice Repopulating Human CD34+Cord Blood CellsHuman Gene Therapy, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Multidrug Resistance 1 Gene Transfer Can Confer Chemoprotection to Human Peripheral Blood Progenitor Cells Engrafted in Immunodeficient MiceHuman Gene Therapy, 2002
- Safety Testing for Replication-Competent Retrovirus Associated with Gibbon Ape Leukemia Virus-Pseudotyped Retroviral VectorsHuman Gene Therapy, 2001
- Progress in the Use of Gene Transfer Methods to Treat Genetic Blood DiseasesHuman Gene Therapy, 2000
- The number and generative capacity of human B lymphocyte progenitors, measured in vitro and in vivo, is higher in umbilical cord blood than in adult or pediatric bone marrowBone Marrow Transplantation, 1999
- Rapid titer determination using quantitative real-time PCRGene Therapy, 1999
- Cis-Active Elements of Friend Spleen Focus-Forming Virus: From Disease Induction to Disease PreventionActa Haematologica, 1998
- Sensitization of human colon tumour cell lines to carmustine by depletion ofO 6-alkylguanine-DNA alkyltransferaseZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow.The Journal of Experimental Medicine, 1987